Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 May;104(5):375-86.
doi: 10.5935/abc.20140216. Epub 2015 Feb 3.

Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes

[Article in English, Portuguese]
Barbara Campos Abreu Marino  1 , Guilherme Abreu Nascimento  2 , Walter Rabelo  3 , Marcos Antônio Marino  2 , Roberto Luiz Marino  3 , Antonio Luiz Pinho Ribeiro  1
Affiliations
Observational Study

Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes

[Article in English, Portuguese]
Barbara Campos Abreu Marino et al. Arq Bras Cardiol. 2015 May.

Abstract

Background: Clinical in-stent restenosis (CISR) is the main limitation of coronary angioplasty with stent implantation.

Objective: Describe the clinical and angiographic characteristics of CISR and the outcomes over a minimum follow-up of 12 months after its diagnosis and treatment.

Methods: We analyzed in 110 consecutive patients with CISR the clinical presentation, angiographic characteristics, treatment and combined primary outcomes (cardiovascular death, nonfatal acute myocardial infarction [AMI]) and combined secondary (unstable angina with hospitalization, target vessel revascularization and target lesion revascularization) during a minimal follow-up of one year.

Results: Mean age was 61 ± 11 years (68.2% males). Clinical presentations included acute coronary syndrome (ACS) in 62.7% and proliferative ISR in 34.5%. CISR was treated with implantation of drug-eluting stents (DES) in 36.4%, Bare Metal Stent (BMS) in 23.6%, myocardial revascularization surgery in 18.2%, balloon angioplasty in 15.5% and clinical treatment in 6.4%. During a median follow-up of 19.7 months, the primary outcome occurred in 18 patients, including 6 (5.5%) deaths and 13 (11.8%) AMI events. Twenty-four patients presented a secondary outcome. Predictors of the primary outcome were CISR with DES (HR = 4.36 [1.44-12.85]; p = 0.009) and clinical treatment for CISR (HR = 10.66 [2.53-44.87]; p = 0.001). Treatment of CISR with BMS (HR = 4.08 [1.75-9.48]; p = 0.001) and clinical therapy (HR = 6.29 [1.35-29.38]; p = 0.019) emerged as predictors of a secondary outcome.

Conclusion: Patients with CISR present in most cases with ACS and with a high frequency of adverse events during a medium-term follow-up.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Graph 1
Graph 1
Study design analyzing CISR patients after treatment. CISR: clinical in-stent restenosis; T: time
Graph 2
Graph 2
Kaplan-Meier curve of cardiovascular mortality and nonfatal heart attack according to CISR treatment (n = 110). Tx performed: treatment performed; CAGB: coronary bypass surgery; PCI: percutaneous coronary intervention; CISR: clinical in-stent restenosis.
Graph 3
Graph 3
Kaplan-Meier curve of cardiovascular mortality and non-fatal heart attack according to CISR with drug-eluting stent (n = 110). CISR: clinical in-stent restenosis.
Graph 4
Graph 4
Kaplan-Meier curve for TVR, TLR and UA according to the treatment of CISR (n = 110). TVR: target lesion revascularization; TLR: target vessel revascularization; UA: unstable angina; CISR: clinical in-stent restenosis; Performed Tx: performed treatment; CAGB: coronary bypass surgery; Balloon PCI: balloon percutaneous coronary intervention.
See this image and copyright information in PMC

References

    1. Serruys PW, de Jaegere P, Kiemeneji F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of baloon-expandable-stent implantation with baloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331(8):489–495. - PubMed
    1. De Labriolle A, Bonello L, Lemesle G, Steinberg DH, Roy P, Xue Z, et al. Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare metal stents. Arch Cardiovasc Dis. 2009;102(3):209–217. - PubMed
    1. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study group. Circulation. 1996;94(6):1247–1254. - PubMed
    1. Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation. 1993;88(3):1310–1323. - PubMed
    1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496–501. - PubMed

Publication types

MeSH terms